Literature DB >> 27339264

The association between muscle strength and activity limitations in patients with the hypermobility type of Ehlers-Danlos syndrome: the impact of proprioception.

Mark Scheper1,2, Lies Rombaut3, Janneke de Vries1,2, Inge De Wandele3, Martin van der Esch1,4, Bart Visser1, Franciska Malfait5, Patrick Calders3, Raoul Engelbert1,2.   

Abstract

PURPOSE: The patients diagnosed with Ehlers-Danlos Syndrome Hypermobility Type (EDS-HT) are characterized by pain, proprioceptive inacuity, muscle weakness, potentially leading to activity limitations. In EDS-HT, a direct relationship between muscle strength, proprioception and activity limitations has never been studied. The objective of the study was to establish the association between muscle strength and activity limitations and the impact of proprioception on this association in EDS-HT patients.
METHODS: Twenty-four EDS-HT patients were compared with 24 controls. Activity limitations were quantified by Health Assessment Questionnaire (HAQ), Six-Minute Walk test (6MWT) and 30-s chair-rise test (30CRT). Muscle strength was quantified by handheld dynamometry. Proprioception was quantified by movement detection paradigm. In analyses, the association between muscle strength and activity limitations was controlled for proprioception and confounders.
RESULTS: Muscle strength was associated with 30CRT (r = 0.67, p = <0.001), 6MWT (r = 0.58, p = <0.001) and HAQ (r = 0.63, p= <0.001). Proprioception was associated with 30CRT (r = 0.55, p < 0.001), 6MWT (r = 0.40, p = <0.05) and HAQ (r = 0.46, p < 0.05). Muscle strength was found to be associated with activity limitations, however, proprioceptive inacuity confounded this association.
CONCLUSIONS: Muscle strength is associated with activity limitations in EDS-HT patients. Joint proprioception is of influence on this association and should be considered in the development of new treatment strategies for patients with EDS-HT. Implications for rehabilitation Reducing activity limitations by enhancing muscle strength is frequently applied in the treatment of EDS-HT patients. Although evidence regarding treatment efficacy is scarce, the current paper confirms the rationality that muscle strength is an important factor in the occurrence of activity limitations in EDS-HT patients. Although muscle strength is the most dominant factor that is associated with activity limitations, this association is confounded by proprioception. In contrast to common belief proprioception was not directly associated with activity limitations but confounded this association. Controlling muscle strength on the bases of proprioceptive input may be more important for reducing activity limitations than just enhancing sheer muscle strength.

Entities:  

Keywords:  Activity limitations; Ehlers–Danlos (hypermobility type); muscle strength; musculoskeletal complaints; proprioception

Mesh:

Year:  2016        PMID: 27339264     DOI: 10.1080/09638288.2016.1196396

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  11 in total

1.  Higher fracture prevalence and smaller bone size in patients with hEDS/HSD-a prospective cohort study.

Authors:  T Banica; M Coussens; C Verroken; P Calders; I De Wandele; F Malfait; H-G Zmierczak; S Goemaere; B Lapauw; L Rombaut
Journal:  Osteoporos Int       Date:  2019-12-24       Impact factor: 4.507

2.  Evidence of ventilatory constraints during exercise in hypermobile Ehlers-Danlos syndrome.

Authors:  Adrien Hakimi; Cyrille Bergoin; Patrick Mucci
Journal:  Eur J Appl Physiol       Date:  2022-08-08       Impact factor: 3.346

3.  An investigation of the control of quadriceps in people who are hypermobile; a case control design. Do the results impact our choice of exercise for people with symptomatic hypermobility?

Authors:  Michael Long; Louise Kiru; Jamila Kassam; Paul H Strutton; Caroline M Alexander
Journal:  BMC Musculoskelet Disord       Date:  2022-06-23       Impact factor: 2.562

Review 4.  Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder.

Authors:  Yael Gazit; Giris Jacob; Rodney Grahame
Journal:  Rambam Maimonides Med J       Date:  2016-10-31

5.  Generalized joint hypermobility, scoliosis, patellofemoral pain, and physical abilities in young dancers.

Authors:  Nili Steinberg; Shay Tenenbaum; Aviva Zeev; Michal Pantanowitz; Gordon Waddington; Gali Dar; Itzhak Siev-Ner
Journal:  BMC Musculoskelet Disord       Date:  2021-02-09       Impact factor: 2.362

Review 6.  Considerations for lactation with Ehlers-Danlos syndrome: a narrative review.

Authors:  Jimi Francis; Darby D Dickton
Journal:  Int Breastfeed J       Date:  2022-01-04       Impact factor: 3.461

7.  Muscle Strength, Muscle Mass and Physical Impairment in Women with hypermobile Ehlers-Danlos syndrome and Hypermobility Spectrum Disorder.

Authors:  Marie Coussens; Bruno Lapauw; Thiberiu Banica; Inge De Wandele; Verity Pacey; Lies Rombaut; Fransiska Malfait; Patrick Calders
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

Review 8.  Rationale and Feasibility of Resistance Training in hEDS/HSD: A Narrative Review.

Authors:  Hannah A Zabriskie
Journal:  J Funct Morphol Kinesiol       Date:  2022-08-20

9.  Psychosocial Influence of Ehlers-Danlos Syndrome in Daily Life of Patients: A Qualitative Study.

Authors:  Inmaculada C Palomo-Toucedo; Fatima Leon-Larios; María Reina-Bueno; María Del Carmen Vázquez-Bautista; Pedro V Munuera-Martínez; Gabriel Domínguez-Maldonado
Journal:  Int J Environ Res Public Health       Date:  2020-09-03       Impact factor: 3.390

Review 10.  A review of respiratory manifestations and their management in Ehlers-Danlos syndromes and hypermobility spectrum disorders.

Authors:  Karan Chohan; Nimish Mittal; Laura McGillis; Laura Lopez-Hernandez; Encarna Camacho; Maxim Rachinsky; Daniel Santa Mina; W Darlene Reid; Clodagh Mai Ryan; Kateri Agnes Champagne; Ani Orchanian-Cheff; Hance Clarke; Dmitry Rozenberg
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.